HTI 1090

Drug Profile

HTI 1090

Alternative Names: HTI-1090; SHR9146

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atridia; Hengrui Therapeutics; Jiangsu Hengrui Medicine Co.
  • Developer Atridia
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 03 May 2017 The US FDA approves clinical registration application for HTI 1090 in Solid tumours in USA
  • 26 Apr 2017 Preclinical trials in Solid tumours in Australia (PO) before April 2017 (PO) (NCT03208959)
  • 26 Apr 2017 Atridia plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly, Metastatic disease) (PO) (NCT03208959)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top